Drugs / WM-A1-3389
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05872867 | Mar 2024 → Feb 2026 | cholangiocarcinoma, colorectal cancer, head and neck cancer, malignant pancreatic neoplasm +2 | Wellmarker Bio | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WM-A1-3389 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05872867 ↗ |
| Route | Intravenous | “WM-A1-3389 administered intravenously, weekly for 21 days of each cycle” NCT05872867 ↗ |
| Target | IGSF1 | “Anti-IGSF1 (Immunoglobulin superfamily member 1)” NCT05872867 ↗ |